Mode
Text Size
Log in / Sign up

Meta-analysis finds CRP has moderate accuracy for diagnosing diabetic foot osteomyelitis

Meta-analysis finds CRP has moderate accuracy for diagnosing diabetic foot osteomyelitis
Photo by Cht Gsml / Unsplash
Key Takeaway
Consider CRP as a moderate screening adjunct for diabetic foot osteomyelitis, not a definitive test.

This meta-analysis of 12 observational diagnostic studies (1828 total patients) with a retrospective cohort component (265 patients with diabetic foot, including 204 with osteomyelitis) assessed the diagnostic accuracy of C-reactive protein (CRP) for diabetic foot osteomyelitis (DFO). The comparator was the presence versus absence of DFO diagnosis.

In the retrospective cohort, CRP showed an area under the curve (AUC) of 0.63 (95% CI: 0.55, 0.71). The optimal cut-off value was 9.57 mg/l, yielding a sensitivity of 74% and specificity of 53%. The meta-analysis pooled results indicated a sensitivity of 74% (95% CI: 63-83%), specificity of 73% (95% CI: 65-79%), and an AUC of 0.79 (95% CI: 0.75, 0.82). A composite model using a 15.20 mg/l cut-off achieved 80% sensitivity but only 53% specificity.

Safety and tolerability data were not reported. Key limitations were not reported, but the evidence is based on observational diagnostic studies with a retrospective component. The practice relevance is restrained: CRP demonstrates moderate diagnostic utility for DFO and could function as a screening adjunct in clinical evaluation, but its standalone accuracy is insufficient for definitive diagnosis.

Study Details

Study typeMeta analysis
Sample sizen = 265
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: To determine the composite cut-off value and diagnostic accuracy of C-reactive protein (CRP) for diabetic foot osteomyelitis (DFO). METHOD: A retrospective study of patients was combined with a meta-analysis. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Pooled sensitivity, specificity and area under the curve (AUC) were calculated via forest plots and summary receiver operating characteristic curves. A composite cut-off model was developed using R 4.4.3 (R Foundation for Statistical Computing, Austria). RESULTS: The experimental cohort comprised 265 patients (204 with DFO and 61 without). The meta-analysis comprised 12 studies, including a total of 1828 patients. The retrospective cohort demonstrated that CRP achieved an AUC of 0.63 (95% confidence interval (CI): 0.55, 0.71) for diagnosing DFO, with an optimal cut-off value of 9.57mg/l (sensitivity 74%, specificity 53%). Meta-analysis revealed pooled sensitivity of 74% (63-83%) and specificity of 73% (65-79%) (AUC=0.79; 95%CI: 0.75, 0.82). The composite model suggested a CRP cut-off of 15.20mg/l (sensitivity 80%, specificity 53%). CONCLUSION: In this study, CRP demonstrated moderate diagnostic utility for DFO and could function as a screening adjunct.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.